Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aston Sci","sponsor":"Timefolio Asset","pharmaFlowCategory":"D","amount":"$22.7 million","upfrontCash":"Undisclosed","newsHeadline":"Aston Sci. Raises USD 22.7 Million Series C Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Aston Sci","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+\/2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Aston Sci

    Menu

    Aston Sci

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aston Sci

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer

              Details:

              Phase 2 clinical trial of AST-301 (pNGVL3-hICD) adopt placebo-controlled randomized design and clinical trial in which AST-301 is administered in combination with standard treatments, in patients with high risk of recurrence following curative surgery.

              Lead Product(s): pNGVL3-hICD,rhuGM-CSF,Pembrolizumab

              Therapeutic Area: Oncology Product Name: AST-301

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aston Sci

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aston Sci. Raises USD 22.7 Million Series C Funding

              Details:

              The raised fund will be used in global clinical development and drug discovery projects. Starting with the phase 2 randomized-controlled clinical trial for AST-301 expected to take place during the second quarter of this year, the value of pipeline will continuously increase.

              Lead Product(s): pNGVL3-hICD,rhuGM-CSF,Pembrolizumab

              Therapeutic Area: Oncology Product Name: AST-301

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Timefolio Asset

              Deal Size: $22.7 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing March 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY